Healionics Closes $5.5 Million Series A-3 Financing Round
SEATTLE, WA, USA/EINPresswire.com/ — Healionics Corporation, a developer of biomaterial-based medical devices, today announced the close of a $5.5 million equity financing round led by Keiretsu Capital with participation by several prominent angel groups. The funds will be used to complete an ongoing human trial and to pursue regulatory clearance and commercialization of Healionics’ novel STARgraft vascular graft.
“STARgraft is a promising solution to the challenge of providing reliable vascular access for dialysis patients,” said Mike Connolly, Chief Executive Officer of Healionics. “The strong support by existing shareholders and new angel investor groups is a testament to the excellent clinical results seen to date in our ongoing human trial.“